<DOC>
	<DOC>NCT02570984</DOC>
	<brief_summary>This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.</brief_summary>
	<brief_title>Controlling and Preventing Asthma Progression and Severity in Kids</brief_title>
	<detailed_description>Prevention/ Disease modification of asthma.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>2447 months at randomization positive allergy to aeroallergen 12 wheezing episodes past year other chronic lung disease besides asthma allergy to study medication</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>